Ulcerative colitis: Bristol Myers Squibb releases results of Zeposia study
2020-10-11
Bristol Myers Squibb announced detailed results from True North, a pivotal, placebo-controlled Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy in adult patients with moderate to severe ulcerative colitis (UC). True North met both primary endpoints, demonstrating highly statistically significant and clinically meaningful results forContinue Reading
